+++Subsequent purchase: Coloplast +++

(from the series: My Investments)

Again u130€. I won't say "No!" to that. Even if it marks a 6-month high. Long-term investing.

The currently smallest active position in my portfolio so increased before the latest figures for the quarter 01/23 come on May 11.

Topics in the upcoming release should be, in addition to the usual mash of numbers, the product updates and first sales figures on LUJATM, HEYLOTM and the first laser device from #coloplast the Thulium Fiber Laser will be. In addition, the integration of ATOS, which was completed last year, will also be an important point.

At this point, the IR department of Coloplast should be praised for putting every IR interested person on the ATOS newsletter for IR right away. Very good! 👍

Analysts estimate Coloplast's earnings per share averaged $0.089 last quarter, up from $0.085 in the year-ago quarter. Furthermore, sales of approximately USD 886.5 million are expected, which would correspond to an increase of 13.8%. For the year, earnings of 0.32 USD per share are expected. Sales should also increase significantly, to USD 3.61 billion.

It remains exciting. Not, however, my decision to continue to remain loyal to this company and to further expand the position in the future.

If you want to read again why Coloplast is my choice for SRI companies in the portfolio, you will find it in this article:

https://getqu.in/7Nbms8/AHy5OO/

$COLO B (+2,15 %)
#sri
#sriinvestments